Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 11/20 | 0.48 |
| ▸ | NMT2 | O60551 | 10/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731630 | 0.87 | NMT1 (0.48) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31721039 | 0.83 | FOLH1 (0.55) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29532146 | 0.79 | SLC15A2 (0.58) | NMT1NMT2TLR2SLC15A2FOLH1 | |
| SCHEMBL30903444 | 0.79 | TGFBR1 (0.45) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30933103 | 0.79 | TGFBR1 (0.45) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL30446798 | 0.79 | SLC15A2 (0.55) | NMT1NMT2TLR2SLC15A2FOLH1 | |
| SCHEMBL31593363 | 0.78 | GRIN2D (0.48) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9273349 | 0.78 | FOLH1 (0.53) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9273337 | 0.78 | FOLH1 (0.53) | NMT1NMT2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL38663332 | 0.77 | TLR2 (0.53) | NMT1NMT2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | NMT1 1060/4885NMT2 755/4885GRIN2D 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.